About US
Contact us
-
Common MS drugs don't prevent disability, study findsCommon multiple sclerosis drugs don't stave off disability, a new study finds. It's a blow for MS patients hoping to stop their disease from progressing, and to drugmakers facing competition from newe2012/7/19
-
J&J drug sales hold their own, thanks to foreign growthFor the second quarter in a row, Johnson & Johnson posted a downward tick in revenues, hobbled by currency losses. Asset writedowns, legal-settlement set-asides, and acquisition costs dug into ear2012/7/18
-
Senator castigates FDA for spying on scientists' emailSen. Charles Grassey, a longtime FDA critic, isn't pulling any punches now that the agency spying on employees has been detailed in the press. In a blistering letter, Grassley demanded to know which F2012/7/18
-
SFDA Deputy Commissioner Wu Zhen meets EU delegation of 2012 DG SANCO/SFDA Working Group Meeting on PharmaceuticalsOn July 10, 2012, Wu Zhen, Deputy Commissioner of the State Food and Drug Administration (SFDA) met with the visiting EU Delegation of 2012 DG SANCO/SFDA Working Group Meeting on Pharmaceuticals. The2012/7/17
-
National Work Conference on Food and Drug Supervision and Management held in BeijingOn July 12-13, 2012, the National Work Conference on Food and Drug Supervision and Management was held in Beijing. At the conference, the progress of the major work of food and drug supervision and ma2012/7/17
-
2,500 Sanofi jobs may be marched off patent cliffSeveral thousand more pharma employees may be marched over the patent cliff as Sanofi ($SNY) confirms that big cuts are coming to its Toulouse site in France. That's where it developed its blockbuster2012/7/16
-
China may not produce for Big Pharma long-termChina, already the third-largest drug market in the world,yesterday was again placed among the 16 "pharmerging" identified by IMS Health's Institute for Healthcare Informatics. The health information2012/7/16
-
Foreign demand saves Ipsen's primary-care plantIpsen's news isn't all bad these days. After its big plans for a new hemophilia drug hit a big snag earlier this week, the drugmaker is announcing plans to keep a French plant it had slated for sale.2012/7/13
-
Emerging markets to dominate as drug sales hit $1.2TIt's no wonder that Big Pharma is looking to emerging markets to lift sales. These fast-growing countries are about the only areas where drug spending will increase significantly. The global drug mark2012/7/13
-
J&J to tighten up on oversight in wake of recalls, lawsuitsJohnson & Johnson ($JNJ) is pledging to keep a sharper eye on drug manufacturing and marketing. Specifically, its board promises to get involved in oversight, to prevent the sort of misbehavior th2012/7/12